<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399943</url>
  </required_header>
  <id_info>
    <org_study_id>MOBILITY-001</org_study_id>
    <nct_id>NCT02399943</nct_id>
  </id_info>
  <brief_title>A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer</brief_title>
  <official_title>Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 study (the second phase in testing a new drug or drug combination) to see&#xD;
      how useful the combination of two drugs, panitumumab and trametinib, are in patients with&#xD;
      advanced colorectal cancer with KRAS, NRAS, or BRAF wild type (genes that are not mutated).&#xD;
&#xD;
      Panitumumab is a drug that is approved by Health Canada for the treatment of advanced&#xD;
      colorectal cancer with KRAS wild type. Panitumumab works by binding to and blocking the&#xD;
      protein, epidermal growth factor receptor (EGFR) from working.&#xD;
&#xD;
      Trametinib is a drug that is approved by Health Canada for the treatment of melanoma with a&#xD;
      mutation in the BRAF gene. Trametinib works by binding to and blocking mitogen-activated&#xD;
      protein kinase kinase (MEK) 1 and MEK2 from working.&#xD;
&#xD;
      Previous studies have shown that the combination of panitumumab and trametinib may be more&#xD;
      useful in KRAS, NRAS, or BRAF wild type colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who experience complete response, partial response, or stable disease</measure>
    <time_frame>24 weeks</time_frame>
    <description>by RECIST 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and proportion of patients who experience side effects.</measure>
    <time_frame>3 years</time_frame>
    <description>by system organ class and preferred term</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving either a complete or partial tumor response</measure>
    <time_frame>3 years</time_frame>
    <description>by RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time period from the first dose of Trametinib and Panitumumab to the first date in which progression or death is observed</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Date of first confirmed response to the first date in which progression is observed</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>KRAS Wildtype</condition>
  <condition>NRAS Wildtype</condition>
  <condition>BRAF Wildtype</condition>
  <arm_group>
    <arm_group_label>Trametinib and Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trametinib: 2 mg QD, orally, continuously.&#xD;
Panitumumab: 6 mg/kg, intravenously, Q2W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <arm_group_label>Trametinib and Panitumumab</arm_group_label>
    <other_name>MEKINIST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <arm_group_label>Trametinib and Panitumumab</arm_group_label>
    <other_name>VECTIBIX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  KRAS/NRAS/BRAF wild type colorectal cancer, not responsive to standard therapies, no&#xD;
             approved or curative therapy, refuse standard therapy&#xD;
&#xD;
          -  Prior 5-FU, oxaliplatin and irinotecan&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1&#xD;
&#xD;
          -  Able to swallow/retain oral drugs&#xD;
&#xD;
          -  Able and agree to have provide tumor tissue/have biopsies&#xD;
&#xD;
          -  Agree to use contraception&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Adequate organ system function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy, radiotherapy, immunotherapy, or other anti-cancer therapies &lt;28 days or&#xD;
             5 half lives&#xD;
&#xD;
          -  Prior EGFR, MEK, or RAF inhibitor or regorafenib&#xD;
&#xD;
          -  Current use of prohibited medications&#xD;
&#xD;
          -  Unresolved side effects&#xD;
&#xD;
          -  GI disease or other condition affecting GI absorption&#xD;
&#xD;
          -  Mucosal or internal bleeding&#xD;
&#xD;
          -  Any major surgery &lt;four weeks&#xD;
&#xD;
          -  HIV, HBV, or HCV positive&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Leptomeningeal disease&#xD;
&#xD;
          -  Brain metastases&#xD;
&#xD;
          -  Unacceptable QTcF interval&#xD;
&#xD;
          -  Significant uncontrolled arrhythmias&#xD;
&#xD;
          -  Acute coronary syndromes, myocardial infarction, coronary angioplasty, or stenting or&#xD;
             bypass grafting &lt; 6 mos.&#xD;
&#xD;
          -  Class II, III, or IV heart failure&#xD;
&#xD;
          -  Other clinically significant ECGs&#xD;
&#xD;
          -  Intra - cardiac defibrillators&#xD;
&#xD;
          -  Cardiac metastases&#xD;
&#xD;
          -  Condition that may interfere with patient safety&#xD;
&#xD;
          -  Hypersensitivity to study drugs&#xD;
&#xD;
          -  Severe or uncontrolled systemic diseases&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Retinal vein occlusion&#xD;
&#xD;
          -  Interstitial lung disease or pneumonitis&#xD;
&#xD;
          -  Active liver or biliary disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Bedard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

